New HIV antibody passes early safety check in 43 volunteers
NCT ID NCT03254277
First seen May 21, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This early-stage study tested a single dose of a lab-made antibody called 3BNC117-LS in 43 adults, both with and without HIV. The main goals were to see if it is safe and how long it remains in the bloodstream. No treatment or prevention benefit was measured; the study focused only on safety and drug behavior.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Rockefeller University
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.